Skip to content

Switching to pegylated interferon a-2b improves the efficacy of NAs-treated chronic hepatitis B patients: A multicenter real-world study

Switching to or addinging on pegylated interferon a-2b improves the efficacy of NAs-treated chronic hepatitis B patients: A multicenter real-world study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086402
Enrollment
Unknown
Registered
2024-07-01
Start date
2023-07-21
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic Hepatitis B

Interventions

Case group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 65 years old 2. HBsAg positive = 6 months before initial NAs treatment 3. Serum HBsAg = 1500 IU/mL, HBeAg-negative and HBV DNA < 200IU/mL after at least 1 year of NAs therapy (NAs include ETV, TDF, TAF, TMF, and ADV)

Exclusion criteria

Exclusion criteria: 1. Received other antiviral or immunomodulatory treatments (including interferon) within one year prior to enrollment 2. Co-infection with other hepatitis viruses, HIV, CMV, etc 3. Decompensated cirrhosis, psychiatric history, uncontrolled epilepsy, uncontrolled autoimmune disease and diabetes, as well as severe infection, retinal disease, heart failure, chronic obstructive pulmonary disease and other basic diseases 4. Pregnancy or having a pregnancy plan in the short term

Design outcomes

Primary

MeasureTime frame
Rate of negative serum HBsAg;Level of serum HBsAg;Change in level of serum HBV DNA ;

Secondary

MeasureTime frame
Scores of liver fibrosis(APRI, FIB-4);Serum aminotransferase levels;Incidence of adverse reactions (fever, leukopenia, abnormal thyroid function, etc.);

Countries

China

Contacts

Public ContactChen enqiang

West China Hospital of Sichuan University

chenenqiang1983@hotmail.com+86 189 8060 6517

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026